Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xvivo Perfusion AB (XVIPF)
:XVIPF
Holding XVIPF?
Track your performance easily
Earnings Data
Report Date
Jan 28, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.13Last Year’s EPS
0.2Same Quarter Last Year
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 26, 2018
|% Change Since: 4.85%
|Next Earnings Date:Jul 20, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a strong quarter with significant growth in the Thoracic and Liver segments, complemented by successful heart trials and strategic acquisitions. However, challenges in the Abdominal and Services segments, along with hurdles in launching Kidney Assist Transport in the U.S., balanced the overall sentiment.Company Guidance
In the XVIVO.ST Q3 2024 earnings call, CEO Christoffer Rosenblad and CFO Kristoffer Nordstrom provided robust guidance on the company's performance and strategic initiatives. XVIVO reported sales of SEK 191 million, marking a 41% organic growth, with EBITDA improving to 21%. The Thoracic segment saw significant growth, driven by increased activities and the U.S. Heart trial. Year-to-date sales reached nearly SEK 600 million, with a 36% growth in local currencies. The company continues to invest in commercial capabilities, with a focus on launching the heart product in Europe and the Kidney Assist Transport in North America. XVIVO is also scaling up production to meet demand, aiming to complete full-scale production by Q2 2025. Additionally, XVIVO's acquisition of FlowHawk is expected to enhance its service offerings. The company's long-term outlook emphasizes sustainable growth and advancing transplant processes globally.Significant Organic Growth
Sales reached SEK 191 million, marking a 41% organic growth, with EBITDA improving to 21%.
Thoracic Segment Performance
Thoracic segment showed strong performance with an organic growth of 54% in disposables and EVLP sales growth of 110% in the U.S.
Heart Trial Success
The U.S. Heart trial showed high interest and activity, with significant improvements in PGD and 76% risk reduction in severe PGD.
Liver Assist Technology
Liver Assist technology showed a 5-year graft survival at 91% in a real-world setting, supporting routine practice for liver transplantations.
FlowHawk Acquisition
Acquisition of FlowHawk to enhance communication in the transplant process and integrate with Xvivo's remote monitoring system.
---
XVIPF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
XVIPF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jan 28, 2025 | $38.14 | $40.38 | +5.87% |
| Oct 24, 2024 | $46.05 | $44.65 | -3.04% |
| Jul 12, 2024 | $39.63 | $47.85 | +20.74% |
| Apr 24, 2024 | $29.48 | $33.53 | +13.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Xvivo Perfusion AB (XVIPF) report earnings?
Xvivo Perfusion AB (XVIPF) is schdueled to report earning on Jan 28, 2025, TBA Not Confirmed.
What is Xvivo Perfusion AB (XVIPF) earnings time?
Xvivo Perfusion AB (XVIPF) earnings time is at Jan 28, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XVIPF EPS forecast?
XVIPF EPS forecast for the fiscal quarter 2024 (Q4) is 0.13.
---